UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

AMENDMENT NO. 1 TO FORM 10-K

(Mark One)

☒	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2021

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________________________ to _________________________

Commission file number 000-54785

GLUCOTRACK, INC.

(Exact name of registrant as specified in its charter)

Delaware		98-0668934
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

8 Ariel Sharon Street P.O. Box 6037607 Or Yehuda, Israel		L3 7760049
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code 972 (8) 675-7878

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act: Common stock, par value $0.001 per share

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K ☒.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐

Non-accelerated filer ☒	Smaller Reporting Company ☒

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		GCTK		Nasdaq Capital Market

The aggregate market value of the voting stock held by non-affiliates is approximately $32,694,000 based on the closing price of $5.33 per share of the registrant’s common stock, as reported on the OTCQB on June 30, 2021, the last business day of the registrant’s most recently completed second fiscal quarter of 2021.

As of March 30, 2022, 15,455,109 shares of the registrant’s common stock, par value $0.001 per share, were outstanding.

DOCUMENTS INCORPORATED BY REFERENCE:

None, except as noted for the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 31, 2021.

Audit Firm ID		Auditor Name		Auditor Location
1375		Fahn Kanne & Co.		Tel-Aviv, Israel

EXPLANATORY NOTE

GlucoTrack, Inc. (“GlucoTrack” or the “Company”) is filing this Amendment No. 1 to Form 10-K (this “Amendment”) to amend our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “Original Filing”), filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2022. The purpose of this Amendment is solely to disclose the information required in Part III (Items 10, 11, 12, 13 and 14) of the Original Filing, which information was previously omitted from the Original Filing in reliance on General Instruction G(3) to Form 10-K. In accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Items 10 through 14 of Part III of the Original Filing are hereby amended and restated in their entirety. In addition, pursuant to Rule 12b-15 under the Exchange Act, the Company is including Item 15 of Part IV of this Amendment, solely to file the certifications required under Section 302 of the Sarbanes-Oxley Act of 2002. Except as described above, this Amendment does not amend any other information set forth in the Original Filing, and we have not updated disclosures included therein to reflect any subsequent events.

TABLE OF CONTENTS

PART III

Item 10.	Directors, Executive Officers and Corporate Governance	3

Item 11.	Executive Compensation	6

Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	10

Item 13.	Certain Relationships, and Related Transactions, and Director Independence	12

Item 14.	Principal Accounting Fees and Services	12

PART IV

Item 15.	Exhibits and Financial Statement Schedules	13

SIGNATURES AND EXHIBIT INDEX

Exhibit Index		13

Signatures		14

PART III

Item 10. Directors, Executive Officers and Corporate Governance.

OUR DIRECTORS

The table below sets forth (1) the names and ages of our Directors as of the date of this Annual Report, (2) all positions with the Company presently held by each such person and (3) the positions held by, and principal areas of responsibility of, each such person during the last five years.

Name	Age	Position

Allen E. Danzig	66	Director, Chair of the Nominating, Governance and Compensation Committee
Dr. Robert Fischell	93	Director, Member of the Audit Committee and Nominating, Governance and Compensation Committee
Luis Malave	59	Director, Member of the Audit Committee and Nominating, Governance and Compensation Committee
Shimon Rapps	42	Director, Chair of the Audit Committee
Andrew Sycoff	55	Director

Allen E. Danzig has served as a Director of the Company since October 31, 2019 and is the Chair of our Nominating, Governance and Compensation Committee. Mr. Danzig most recently served as Vice President, Assistant General Counsel and Assistant Secretary of L3Harris Technologies, Inc., a global aerospace and defense technology contractor, with $17 billion in annual revenue. Prior to its merger with Harris Corporation in June 2019, Mr. Danzig served as Vice President, Assistant General Counsel and Assistant Secretary at L3 Technologies, Inc. where he had been employed since 2006. Prior to his employment at L3, Mr. Danzig served in management positions with Celanese Corporation, a global chemical and specialty materials company, and The Hertz Corporation, one of the world’s largest vehicle and equipment rental companies. He received his undergraduate degree from Adelphi University and law degree from Pace University School of Law and is a member of the New York State Bar. The Board has determined that Mr. Danzig is suited to serve due to his extensive legal and corporate governance experience.

Dr. Robert Fischell has served as a Director of the Company since 2010. He also serves on GlucoTrack’s Nominating, Governance and Compensation Committee and Audit Committee. Dr. Fischell is an inventor and serial entrepreneur with over 160 issued U.S. patents. Starting in 1959, Dr. Fischell spent over 30 years with the Johns Hopkins University Applied Physics Laboratory, which resulted in 53 patents in both aerospace and biomedical technology. His interests at Johns Hopkins then turned to the invention of new medical devices such as pacemakers and implantable heart defibrillators. Starting in 1969, Dr. Fischell began the formation of 14 private companies that licensed his patents on medical devices. These companies include Pacesetter Systems, Inc. (purchased by Siemens and now part of St. Jude Medical, Inc.), IsoStent, Inc. (merged with Cordis Company, a Johnson and Johnson Company), NeuroPace, Inc., Neuralieve, Inc., Angel Medical Systems, Inc., and Svelte Medical Systems, Inc. As it relates to diabetes management devices, he was the inventor of the first implantable insulin pump (which became Minimed, which was sold to Medtronic). Dr. Fischell’s honors include Inventor of the Year for the USA in 1984, election to the National Academy of Engineering in 1989, the Distinguished Physics Alumnus Award of the University of Maryland, and several medals for distinguished accomplishments in science, engineering and innovation. In 2004, Discover magazine gave Dr. Fischell their annual Technology for Humanity award. In 2008, Dr. Fischell received the honorary degree of Doctor of Humane Letters from the Johns Hopkins University in recognition of his many lifesaving inventions. From June 2009 until March 2011, Dr. Fischell was a director of InspireMD, Inc. (OTCBB: NSPR), a medical device company focusing on the development and commercialization of its proprietary stent system, MGuard. Dr. Fischell received his BSME degree from Duke University and MS and Sc.D. degrees from the University of Maryland. At the White House on May 16, 2016, President Obama presented to Dr. Fischell the National Medical of Technology and Innovation, the highest award in the USA for achievements in innovative technology. The Board has determined that Dr. Fischell is suited to serve due to his extensive diabetes and medical device experience.

Luis Malave has served as a Director of the Company since June 22, 2021 and serves on our Audit Committee and Nominating, Governance and Compensation Committee. Mr. Malavé brings more than 30 years of leadership experience in the MedTech industry, primarily in diabetes management, spanning all company stages, from private startups to large-cap publicly listed companies. He has extensive expertise in product development, operations, marketing, strategic partnerships, and US FDA regulatory strategy. Since October 2017, Mr. Malavé has served as President of EOFLOW CO. Ltd., a company listed on the Korea Stock Exchange that has developed a wearable disposable insulin pump. From October 2014 to June 2016, he was COO of Mikroscan Technologies. Prior to that, Mr. Malavé was the President and CEO of Palyon Medical, maker of an implantable drug-delivery system that spun out from German medical-technology giant Fresenius SE. Prior to Palyon, he spent nearly a decade at insulin pump maker Insulet Corp., including as its Senior Vice President of Research, Development and Engineering, and as Chief Operating Officer. He also held various senior positions at Medtronic and MiniMed, overseeing product development of various diabetes management devices. Mr. Malavé earned his Bachelor’s degree in Mathematics and Computer Science from the University of Minnesota, a Master’s degree in Software Engineering from the University of St. Thomas, and an MBA from the University of Maryland.

Shimon Rapps has served as a Director of the Company since July 31, 2019. He is also Chair of GlucoTrack’s Audit Committee. Mr. Rapps serves as Head of Investment Banking at Andrew Garrett, Inc., a full-service investment bank providing wealth management and corporate advisory services, where he has been employed since early 2005. In this role, he oversees all of Andrew Garrett’s corporate finance, investment banking and corporate advisory activities. His experience spans equity and debt financings, mergers and acquisitions, private placements and IPO’s. He has extensive expertise with both public and private, emerging growth and middle market companies, and regularly advises CEO’s, CFO’s and Boards of Directors on matters of corporate governance and strategy. He holds the Series 7, 24, 63, and 66 licenses. The Board has determined that Mr. Rapps is suited to serve due to his extensive investment banking and public company experience.

Andrew Sycoff has served as a Director of the Company since July 8, 2019. Mr. Sycoff is the founder, Chief Executive Officer and Chairman of the Board of Andrew Garrett, Inc., a full-service investment bank providing wealth management and corporate advisory services, for which he has served as CEO and Chairman continuously since 1992. Client sectors include high net worth individuals and early to middle market stage companies. Mr. Sycoff holds Series 7 and 24 licenses. Mr. Sycoff has been actively investing in and advising companies for over 25 years and has extensive experience in the areas of securities brokerage, Capital Markets, Corporate Advisory and Mergers & Acquisitions. Mr. Sycoff previously served on the board of Brokerage America and Paragon Industries Corp., an electronics contract manufacturer. The Board has determined that Mr. Sycoff is suited to serve due to his extensive investment banking and public company experience.

OUR EXECUTIVE OFFICERS

The table below sets forth the names and ages of our executive officers as of the date of this Annual Report and all positions with the Company presently held by each such person. Immediately following the table is biographical information for each of our executive officers.

Name	Age	Position
Erez Ben Zvi	44	General Manager and VP of Product
Jolie Kahn	57	Chief Financial Officer
Paul Goode	54	President and Chief Operating Officer
Shalom Shushan	50	Chief Technology Officer

Paul V. Goode PhD was named Chief Operating Officer of the Company on November 1, 2021, and previously served as a Director of the Company from December 17, 2020 to November 1, 2021. Mr. Goode most recently served as Vice President of Product Development at Orchestra Biomed where he oversees development of its implantable cardiac stimulator system for hypertension. Prior to Orchestra, from 2010 until July 2019 Paul served in several executive roles at EndoStim, including Senior Vice President of R&D, Chief Technology Officer, and Interim CEO. In October 2019, subsequent to Mr. Goode’s employment, Endostim entered into an assignment of all of its assets for the benefit of its creditors. From 2006 through 2010 he served as VP of Research and Development at Metacure and from 2004 through 2006 Mr. Goode served as Director of Engineering at Impulse Dynamics. Prior to that, Mr. Goode was employed as Director of Engineering at DexCom and as Senior Engineer at MiniMed.

Erez Ben Zvi was named VP of Product on July 13, 2020 and additionally named General Manager on February 8, 2021. Erez brings 15 years of exceptional product management and leadership experience developing rapid growth strategies for medical device companies. Erez joins GlucoTrack from 3D Systems Healthcare, a NASDAQ-listed 3D printing and digital manufacturing company where he spent 6 years in senior roles, including as Head of Global Market Development. In this role, Erez led all medical 3D printing and VR software solutions, designing the go-to-market strategy and overseeing global market development and expansion, as well as leading the product sales and growth at Point-of-Care. Previously, and until its acquisition by 3D Systems, Erez was leading the clinical application product portfolio at Simbionix, a leader in 3D virtual reality surgical simulation and training where he was responsible for the positioning and launch of their flagship patient-specific simulation product line. Prior to that, Erez held senior positions at Paieon Medical where he spearheaded commercialization of the company’s cardiac catheterization real-time navigation system and led the company through ISO certification and product applications to FDA, CE and Health Canada. He holds a B.Tech degree in Industrial Engineering from Shenkar College of Engineering and Design, and an M.B.A from Bar-Ilan University.

Jolie Kahn, who was named Interim Chief Financial Officer in August 2019, has an extensive background in corporate finance and corporate and securities law. She has been the proprietor of Jolie Kahn, Esq. since 2002. Ms. Kahn has also acted in various corporate finance roles, including extensive involvement of preparation of period filings and financial statements and playing an integral part in public company audits. She also works with companies and hedge funds in complex transactions involving the structuring and negotiation of multi-million-dollar debt and equity financings, mergers, and acquisitions. Ms. Kahn has practiced law in the areas of corporate finance, mergers & acquisitions, reverse mergers, and general corporate, banking, and real estate matters. She represents both public and private companies, hedge funds, and other institutional investors in their role as investors in public companies. Ms. Kahn holds a BA from Cornell University and a J.D. magna cum laude from the Benjamin N. Cardozo School of Law.

Shalom Shushan joined the Company on November 9, 2020, as its Chief Technology Officer. Mr. Shushan leads all technology and research and development activities for GlucoTrack and serves on the Company’s executive leadership team. With more than 20 years in technology and product development leadership roles, Shalom brings extensive experience in sensor technologies, machine learning, algorithm design, product portfolio strategy, and other critical engineering expertise in the field of consumer, security and medical device technologies, including multiple healthcare related wearables. In addition, Mr. Shushan’s leadership experience ranges from managing large global multi-site and cross-functional teams to working with and expanding nascent technology companies, including a medical device startup that he founded. Most recently, Mr. Shushan spent 8 years as VP of Research and Development at Crow Technologies, Ltd., where he drove the technical vision and strategy and was responsible for the development and engineering of its IoT, Smart Home and Telehealth platforms. Previously, Shalom co-founded and was CEO of Nayos Ltd., a privately held embedded solution design house and was CEO and CTO of Bio-Guard following its merger with Nayos. Shalom holds a BS degree in Electrical and Computer Engineering from Ben-Gurion University with a specialization in signal and image processing. Mr. Shushan is resigning from the Company effective May 22, 2022.

CORPORATE GOVERNANCE

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Exchange Act and regulations of the SEC thereunder requires our officers and directors, and persons who own more than 10% of a registered class of our equity securities to file reports of ownership and changes of ownership with the SEC. The Company is not reporting on this compliance in this Annual Report

Code of Business Conduct and Ethics

GlucoTrack has adopted a code of ethics that applies to its Chief Executive Officer and its senior financial officers (currently consisting only of the Chief Financial Officer). This code of ethics is available on GlucoTrack’s website at www.integrity-app.com. If GlucoTrack makes any substantive amendments to the code or grants any waiver, including any implicit waiver, from a provision of the code to its principal executive, financial or accounting officer, it will disclose the nature of the amendment or waiver on its website or in a report on a Current Report on Form 8-K filed in accordance with the rules and regulations of the SEC. The Company will provide to any person without charge, upon five days’ written request, a copy of the code of ethics.

Compensation and Nominating and Corporate Governance Committee

The members of the Nominating, Governance and Compensation Committee of the Board are Mr. Allen E. Danzig (Chairman), Mr. Malave and Dr. Robert Fischell. Our Board has determined that these directors (except for are “independent” as defined by the rules of the SEC. The purposes and powers of the Nominating and Corporate Governance Committee include (i) identifying potential qualified nominees for director and recommend to the Board for nomination candidates for the Board, (ii) developing the Company’s corporate governance guidelines and additional corporate governance policies, and (iii) exercising such other powers and authority as shall from time to time be assigned thereto by resolution of the Board. The Nominating and Corporate Governance Committee adopted the Nominating and Corporate Governance Committee charter on July 5, 2016, which sets forth the duties and responsibilities of the Nominating and Corporate Governance Committee.

Audit Committee and Audit Committee Financial Expert

The members of the Audit Committee of the Board are Mr. Shimon Rapps (Chairman), Mr. Malave and Dr. Robert Fischell. Our Board has determined that these directors are “independent” as defined by the rules of the SEC. The primary role of the Committee is to oversee the financial reporting and disclosure process. To fulfill this obligation, the Committee relies on: management for the preparation and accuracy of the Company’s financial statements; both management and the Company’s internal audit department/management for establishing effective internal controls and procedures to ensure the Company’s compliance with accounting standards, financial reporting procedures and applicable laws and regulations; and the Company’s independent auditors for an unbiased, diligent audit or review, as applicable, of the functions of the audit committee are performed by the full Board. Each member of the Committee shall be independent in accordance with the requirements of Rule 10A-3 of the Exchange Act and the NASDAQ Listing Rules. No member of the Committee can have participated in the preparation of the Company’s or any of its subsidiaries’ financial statements at any time during the past three years.

The Board has determined that Mr. Rapps is an “Audit Committee Financial Expert” as that term is defined in Item 407(d)(5)(ii) of Regulation S-K.

EXECUTIVE COMPENSATION

Summary Compensation Table

The following table summarizes compensation of our three highest paid named executive officers, as of December 31, 2021 and 2020.

Name and Principal Position	Year	Salary		Bonus		Option Awards		All other Compensation(1)		Total Compensation

Jolie Kahn	2020	$	120,000	$	-	$	-	$	-	$	120,000
Chief Financial Officer	2021	$	120,000	$	-	$	-	$	-	$	120,000

Erez Ben Zvi	2020	$	61,968	$	-	$	24,975	$	18,765	$	105,708
General Manager and VP of Product	2021		183,269				76,219		48,578		308,066

Shalom Shushan	2020	$	36,793	$	-	$	-	$	-	$	36,793
Chief Technology Officer	2021		203,142				22,206		58,913		284,261

(1)

Includes contributions to the (a) Severance Pay- Fund, (b) retirement plan feature of Managers’ Insurance (Kupat Gemel), (c) disability insurance (Ovdan Kosher Avoda) and (d) statutory national insurance (Bituach Leumi). Also includes automobile expenses and cellular communications expenses paid by GlucoTrack.

Employment Agreements

Set forth below are summaries of the material terms of the employment agreements of our current named executive officers.

Erez Ben-Zvi

Integrity Applications, Ltd., a wholly owned subsidiary of the Company, entered into an amended employment agreement with Mr. Ben-Zvi as of February 8, 2021. In addition to receipt of a one time bonus of $18,000. the Employee shall be entitled to a gross monthly salary of NIS 33,594 (the “Base Salary”). In addition, in consideration for overtime hours that the Employee may work during the month, the Employee shall receive a global payment of NIS 11,198 (the “Global Overtime Compensation”, and together with the Base Salary, the “Salary”). The Global Overtime Compensation has been determined based on the Company’s estimation of the average of overtime hours per month that the Employee’s position may require.

The Company granted Mr. Ben-Zvi annual award of NIS 210 thousand worth (approximately $ 61 thousand) of restricted stock units (the “RSU”) effective as of the employee Start Date and on each one-year anniversary following the employee Start Date subject to the approval of the board of directors (the “additional RSU”). The RSU and each of the Additional RSU (if approved by the board of directors), as applicable, shall be based on the stock price at actual the date of grant (and not lower than US$ 0.40 per share). 1/12 of the RSUs shall vest and become nonforfeitable three months following the Start Date, and an additional 1/12 of the RSUs shall vest and become nonforfeitable at the end of every 3-months period thereafter, provided that the employee continues to be employed by the Company at the applicable date of vesting. The vesting schedule shall be also applied to each of the Additional RSUs granted, mutatis mutandis, such that the vesting period of each of the respective Additional RSU shall commence from its actual date of grant.

Shalom Shushan

Integrity Applications, Ltd., a wholly owned subsidiary of the Company, entered into an employment agreement with Mr. Shushan as of November 9, 2020. The summary terms of the employment agreement are as follows:

The Employee shall be entitled to a gross monthly salary of NIS 41,250 (the “Base Salary”). In addition, in consideration for overtime hours that the Employee may work during the month the Employee shall receive a global payment of NIS 13,750 per month (the “Global Overtime Compensation”, and together with the Base Salary, the “Salary”). The Global Overtime Compensation has been determined based on Company’s knowledgeable estimation of the average of overtime hours per month that the Employee’s position requires. The Employee shall have 23 annual vacation days.

Subject to the terms and conditions of the Company Share Incentive Plan, as amended and restated from time to time (the “Plan”), the Company shall recommend the Board of Directors of the Parent (the “Parent Board”) to grant the Employee one time award (the “Award”) of NIS 90,000 worth of restricted stock units (the “RSU”) effective as of the Start Date. Furthermore, on each one-year anniversary following the Start Date, Company shall grant the Employee with NIS 60,000 worth of restricted stock units (the “Additional RSU’’). Both the RSU and each of the Additional RSU, as applicable, shall be based on the stock price at actual the date of grant (and not lower than US$ 0.40 per share). 1/12 of the RSUs shall vest and become nonforfeitable three months following the Start Date, and an additional 1/12 of the RSUs shall vest and become nonforfeitable at the end of every 3-months period thereafter, provided that the Employee continues to be employed by the Company at the applicable date of vesting. The vesting schedule shall be also applied to each of the Additional RSUs granted to the Employee, mutatis mutandis, such that the vesting period of each of the respective Additional RSU shall commence from its actual date of grant.

Employee will participate in the annual incentive plan at a level target of up to NIS 60,000 based on the achievement of certain company and individual performance metrics as determined by the Company’s Board of Directors. Company shall have the full discretion to amend and\or cancel the Bonus Plan suggested at any time, at its sole discretion.

Paul Goode

On October 19, 2021, Paul V. Goode was appointed as President and Chief Operating Officer of GlucoTrack, effective November 1, 2021 (“Effective Date”). He had served as a member of the Company’s Board of Directors since December 17, 2020. Concurrent with his new appointment, Mr. Goode stepped down from the Board.

Mr. Goode most recently served as Vice President of Product Development at Orchestra Biomed where he oversaw development of its implantable cardiac stimulator system for hypertension. Prior to Orchestra, from 2010 until July 2019 Paul served in several executive roles at EndoStim, including Senior Vice President of R&D, Chief Technology Officer, and Interim CEO. From 2006 through 2010 he served as VP of Research and Development at Metacure and from 2004 through 2006 Mr. Goode served as Director of Engineering at Impulse Dynamics. Prior to that, Mr. Goode was employed as Director of Engineering at DexCom and as Senior Engineer at MiniMed. Paul received his BS, MS and PhD degrees from North Carolina State University.

In this role, Goode will lead the company’s operations, overseeing strategy, design, manufacturing, business and product development and begin to build the U.S. infrastructure in preparation for the U.S. clinical trials of GlucoTrack. He will devote such time as necessary to perform his duties but shall be able to pursue other professional opportunities at the same time. His base salary shall be $175,000 per year, and he shall be entitled to a cash bonus of up to 20% of his annual base salary as determined by the Company’s Compensation Committee and shall be granted options to purchase up to One and half Percent (1.5%) of the fully diluted common stock, par value $0.001 per share, of the Company (“Common Stock”) as of the Effective Date, with a per share exercise price equal to the greater of (A) $5.20 per share or (B) the closing price of a share of Common Stock on the Effective Date, as reported by Bloomberg L.P., which shall vest in equal monthly installments over a three year period following the Effective Date.

The bonus and equity incentives shall be subject to clawback rights if there is a misstatement of financials which changes any metrics upon which a bonus or incentives are based and the clawback will be pro rata based upon the changes in the financials with respect to the effect on any underlying metrics.

Jolie Kahn

The Company also entered into a Consulting Agreement with Ms. Kahn for her services as Interim CFO. She is compensated $10,000 per month for her services. The Agreement was for an initial term of six months which expired on January 31, 2020 and was renewed by the Company on February 5, 2020 for an additional six month term and may has been further orally extended for successive six-month terms and may be terminated by either party on 30 days’ notice. Ms. Kahn also acts as US counsel to the issuer and is compensated separately for legal services provided.

Outstanding Equity Awards as of December 31, 2021

The following table sets forth for each of GlucoTrack’s named executive officers certain information regarding unexercised options as of December 31, 2021:

Name

Number of Securities Underlying Unexercised Options (#) Exercisable

Number of Securities Underlying Unexercised Options (#) Unexercisable

Option Exercise Price ($)

Option Expiration Date

Erez Ben Zvi

5,915

18,115

N/A

Shalom Shoshan

1,716

7,079

N/A

DIRECTOR COMPENSATION

The following table sets forth information with respect to the compensation of our directors as of December 31, 2021:

	Year End Total
	Cash		Common Shares		Total
Allen Danzig	$	31,250	$	18,750	$	50,000
Robert Fischell	$	48,000	$	0	$	48,000
Paul Goode	$	18,958	$	10,208	$	29,167
Shimon Rapps	$	50,000	$	0	$	50,000
Luis Malave	$	9,722	$	8,750	$	18,472
Andrew Sycoff	$	41,500	$	0	$	41,500
Total	$	199,431	$	37,708	$	237,139

The Company’s Board fee schedule is as follows:

Fee Table	Annual		Quarter
Board	$	35,000	$	8,750
Committee Member	$	6,500	$	1,625
Committee Chair	$	15,000	$	3,750

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information regarding the ownership of our Common Stock within 60 days of April 29, 2022 by:

●	each person known to us to be the beneficial owner of more than 5% of our outstanding shares of common stock;
●	each of our named executive officers and our current directors; and
●	all of our executive officers and directors as a group.

Except as otherwise indicated below, the address of each beneficial owner listed in the table is c/o GlucoTrack, Inc., 8 Ariel Sharon Street, P.O. Box 6037607, Or Yehuda, Israel.

We have determined beneficial ownership in accordance with the rules of the SEC. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons and entities named in the table below have sole voting and investment power with respect to all shares of common stock that they beneficially own, subject to applicable community property laws.

Applicable percentage ownership is based on 15,452,285 shares of common stock outstanding on April 29, 2022. In computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed as outstanding shares of common stock subject to options held by that person that are currently exercisable or exercisable within 60 days of April 29, 2022. We did not deem these exercisable shares outstanding, however, for the purpose of computing the percentage ownership of any other person. The applicable footnotes are an integral part of the table and should be carefully read in order to understand the actual ownership of our securities, particularly by the 5% stockholders listed in the table.

Name of Beneficial Owner	Number of Shares Beneficially Held		Number of Preferred, RSUs, Options and Warrants Exercisable within 60 days			Total Shares Beneficially Owned
						Number		Percent
Erez Ben-Zvi		-		9,921			9,921		-
Allen E. Danzig		15,048		-			15,048		*	%
Dr. Robert Fischell		35,048		3,197	(1)		38,245		*	%
Paul Goode		1,950		63,714	(2)		65,664		*	%
Jolie Kahn		-		-			-		*	%
Luis Malave		4,332					4,332		*
Shimon Rapps		10,598		-	(3)		10,598		*	%
Shalom Shushan		-		3,184			3,184		*	%
Andrew Sycoff		8,171		142,071	(4)		150,242		*	%
James Thrower				43,716			43,716		*	%
All Executive Officers and Directors as a group (10 persons)							297,234		1.9	%

Principal Stockholders
John A Ballantyne Rev Trust 08/01/2017		5,157,888			(5)		5,157,888		33.3	%

(1) Ownership includes (i) 31,733 shares of Common Stock owned individually, (ii) 3,316 owned jointly by Dr. Fischell and his wife; and (iii) 3,197 Options deemed vested within 60 days of April 29, 2022.

(2) Options deemed vested within 60 days of April 29, 2022.

(3) SDR Diversified Holdings, LLC, an entity owned by Leah Rapps, the wife of Shimon Rapps, owns 3,578 shares of common stock and 1,226,556 warrants to purchase shares of our Common Stock. Leah Rapps has voting control and investment power over SDR Diversified Holdings, LLC. Ms. Rapps also owns 2,099 shares in her personal name. Mr. Rapps disclaims beneficial ownership in the shares and warrants held by his wife and by SDR Diversified Holdings, LLC.

(4) Ownership includes: (i) 8,171 shares of common stock owned by Mr. Sycoff; and (ii) 142,071 shares of common stock issuable upon the exercise of warrants owned by Andrew Garrett, Inc. Mr. Sycoff has voting power and investment control over the shares of common stock held by Andrew Garrett, Inc. Alma Diversified Holdings LLC, an entity owned by Sharon Sycoff, the wife of Mr. Sycoff owns (i) 105,010 shares of common stock; and (ii) 3,013,327 shares of common stock issuable upon the exercise of warrants. Sharon Sycoff has voting power and investment control over the shares and warrants held by Alma Diversified Holdings LLC and Mr. Sycoff disclaims beneficial ownership in the shares and warrants held by Alma Diversified Holdings LLC.

(5) In addition, the John A. Ballantyne Revocable Trust 08/01/2017 owns additional shares of common stock acquirable within 60 days, each of which is subject to a Blocker Limitation. However, the percentage ownership by the John A. Ballantyne Revocable Trust 08/01/2017 is currently in excess of such Blocker Limitations, and as a result, such Blocker Securities have been excluded from the table. These Blocker Securities consist of 378,719 warrants. The address of John A. Ballantyne Rev Trust 08/01/2017 is 7410 Claire Drive South, Fargo ND 58104. John A. Ballantyne has voting and investment control over the shares held by John A. Ballantyne Rev Trust 08/01/2017.

* Less than 1% ownership.

Changes in Control

There are no arrangements known to the Company the operation of which may at a subsequent date result in a change in control of the Company.

Item 13. Certain Relationships and Related Transactions, and Director Independence.

Except as set forth below, GlucoTrack is not aware of any transactions since the beginning of its last fiscal year or any proposed transactions in which GlucoTrack was or is a party, in which (1) the amount involved exceeded the lesser of $120,000 or 1% of the average of GlucoTrack’s total assets at year-end for the last two completed fiscal years and (2) in which a director, director nominee, executive officer, holder of more than 5% of GlucoTrack’s Common Stock or Preferred Stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest.

In 2020, Andrew Garrett, Inc., which is controlled by one of our directors, Andrew Sycoff, received from us, cash of $1,980,000 ($1,950,000 for Placement Agent fees relating to our 2020 private placement and $30,000 for Advisory fees that were earned in 2019) and 3,750,000 warrants for Placement Agent fees relating to our 2020 private placement.

Director Independence

GlucoTrack is currently listed on the Nasdaq Capital Market and follows its rules that a majority of the Board of Directors must be comprised of independent directors. The independence rules include a series of objective tests, including that an “independent” person will not be employed by GlucoTrack and will not be engaged in various types of business dealings with GlucoTrack. Applying these rules and based on representations from the directors with respect to their independence thereunder, the Board has determined that each of the current members of GlucoTrack’s Board of Directors is independent, except for Mr. Sycoff, and, therefore, a majority of the members of the Board are independent directors.

Principal Accounting Fees and Services. Audit Fees

Fees for services rendered by Fahn Kanne & Co. (“Fahn Kanne”) for professional services rendered for the 2021 and 2020 audit of our annual financial statements, review of financial statements included in quarterly reports on Form 10-Q in 2021 and 2020 and out of pocket expenses, totaled approximately $83,000 and $72,000 for 2021 and 2020, respectively.

Tax Fees

GlucoTrack did not pay Fahn Kanne any fees in 2021 and paid $7500 in 2020 for assurance and related services reasonably related to the performance of the audit or review of the GlucoTrack’s financial statements.

All Other Fees

GlucoTrack did not pay any other fees to Fahn Kanne in 2020 and paid $11,000 in 2021 for review and consent on its Form S-3 registration statement.

Policy on Pre-Approval of Audit and Permissible Non-Audit Services of Independent Auditors

The Board is solely responsible for the pre-approval of all audit and non-audit services to be provided by the independent accountants. The Board approved all of the fees paid to Fahn Kanne for the years ended December 31, 2021 and 2020.

PART IV

Item 15. Exhibits, Financial Statement Schedules.

(a) Document List

(1) Financial Statements:

The financial statements of the Company were filed with our Form 10-K filed on April 13, 2021 as Part II, Item 8 of that report.

(2) Financial Statement Schedules:

None.

(3) Exhibits:

ITEM 15. Exhibits and Financial Statement Schedules.

(a)(3) Exhibits

31.1	Certification required pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification required pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized as of April 29, 2022.

	GLUCOTRACK, INC.

	By:	/s/ Paul Goode
	Name:	Paul Goode
	Title:	COO (Principal Executive Officer)

	By:	/s/ Jolie Kahn
	Name:	Jolie Kahn
	Title:	Chief Financial Officer (Principal Financial Officer)

SEC Form 10-K/A filed by GlucoTrack Inc. (Amendment)